arrow
G

Gerasimos Aravantinos

university hospital attikon
H指数:47
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

整合多组学分析以确定卵巢癌风险区域的遗传和功能机制

2024-06-016
PRE
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes

早期乳腺癌患者采用环磷酰胺与表柔比星序贯、密集给药,随后序贯多西他赛辅助治疗的十年临床疗效、毒性和依从性:一项由希腊肿瘤协作组开展的观察性研究(HE 10/10),并同步探讨肿瘤浸润淋巴细胞的临床意义

BREAST
IF7.9
2024-02-014
OAAI
Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug a Role?
2023-06-010
PRE
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

曲妥珠单抗时代的剂量密集序贯辅助化疗: 希腊肿瘤协作组HE10/05 III期试验的最终长期结果

2022-05-242
OA
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: Final long-term results of the hellenic cooperative oncology group phase III HE10/05 trial

曲妥珠单抗时代的剂量密集序贯辅助化疗: 希腊肿瘤协作组HE10/05 III期试验的最终长期结果

2022-02-150
PRE
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

一项观察性研究,评估在希腊实际临床环境中使用阿法替尼治疗的晚期EGFR突变阳性非小细胞肺癌患者表皮生长因子受体 (EGFR) 突变的分子流行病学和直接医疗费用

2021-08-012
OAAI
Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?

上皮性卵巢癌患者的肿瘤基因分型和同源重组修复基因变异: 致病性足够吗?

2021-06-011
OAAI
Prevalence and prognostic role of inherited germline mutations in cancer predisposing genes in unselected patients with pancreatic cancer

未经选择的胰腺癌患者中癌症易感基因遗传种系突变的患病率和预后作用

2020-07-010
OAAI
ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
2020-05-161
PREAI
Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials

后曲妥珠单抗时代早期乳腺癌 (BC) 患者剂量密集序贯辅助化疗的5年实际生存率: 3项临床试验的汇总分析

2020-05-010
OAAI
Real-world multicenter, prospective study of the effects of nab-paclitaxel on clinical outcomes and quality of life of patients with metastatic breast cancer in Greece. The 'ABReast' study
2020-02-150
PRE
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group

细胞周期蛋白依赖性激酶4/6 (CDK4/6) 抑制剂联合内分泌治疗的晚期乳腺癌患者的真实世界临床结果和毒性数据以及经济方面: 希腊合作肿瘤学小组的经验

2020-01-0126
OAAI
Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab

曲妥珠单抗治疗晚期乳腺癌患者的细胞周期蛋白D1差异激活及其对预后的影响

2019-01-014
OAAI
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI plus Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer

AMALTHEA: 希腊肿瘤协作组 (HeCOG) 的前瞻性单臂研究,评估一线FOLFIRI联合阿柏西普治疗6个月后阿柏西普维持治疗转移性结直肠癌患者的疗效和安全性

2018-12-0111
PREAI
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

不同组织型上皮性卵巢癌12个新的易感位点的鉴定

2017-03-27325
OAAI
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

希腊合作肿瘤小组乳腺癌辅助试验中骨桥蛋白与特定预后因素和生存率的关联

2017-02-1321
OAAI